{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:20:15Z","timestamp":1791994815288,"version":"4.4.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004242","name":"Princess Nourah Bint Abdulrahman University","doi-asserted-by":"publisher","award":["PNURSP2026R854"],"award-info":[{"award-number":["PNURSP2026R854"]}],"id":[{"id":"10.13039\/501100004242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12403-8","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:41:55Z","timestamp":1784266915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Celastrol at the obesity\u2013cancer interface: critical appraisal of molecular mechanisms, preclinical evidence, and translational barriers"],"prefix":"10.1007","volume":"53","author":[{"given":"Asma B.","family":"Omer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakir","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Masih Uzzaman","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rekha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"12403_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/bs.ircmb.2024.03.007","volume":"387","author":"YV Nguyen Thi","year":"2024","unstructured":"Nguyen Thi YV, Vu TD, Nguyen Thi LH, Chu DT (2024) Epigenetic contribution to the relationship between obesity and cancer. Int Rev Cell Mol Biol 387:195\u2013213. https:\/\/doi.org\/10.1016\/bs.ircmb.2024.03.007","journal-title":"Int Rev Cell Mol Biol"},{"key":"12403_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"12403_CR3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","volume":"403","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2024","unstructured":"NCD Risk Factor Collaboration (NCD-RisC) (2024) Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403:1027\u20131050. https:\/\/doi.org\/10.1016\/S0140-6736(23)02750-2","journal-title":"Lancet"},{"key":"12403_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1373\/clinchem.2017.277376","volume":"64","author":"GA Colditz","year":"2018","unstructured":"Colditz GA, Peterson LL (2018) Obesity and cancer: evidence, impact, and future directions. Clin Chem 64:154\u2013162. https:\/\/doi.org\/10.1373\/clinchem.2017.277376","journal-title":"Clin Chem"},{"key":"12403_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41574-018-0126-x","volume":"15","author":"DF Quail","year":"2019","unstructured":"Quail DF, Dannenberg AJ (2019) The obese adipose tissue microenvironment in cancer development and progression. Nat Rev Endocrinol 15:139\u2013154. https:\/\/doi.org\/10.1038\/s41574-018-0126-x","journal-title":"Nat Rev Endocrinol"},{"key":"12403_CR6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1158\/1940-6207.CAPR-16-0322","volume":"10","author":"C Himbert","year":"2017","unstructured":"Himbert C et al (2017) Signals from the adipose microenvironment and the obesity-cancer link-a systematic review. Cancer Prev Res (Phila) 10:494\u2013506. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-16-0322","journal-title":"Cancer Prev Res (Phila)"},{"key":"12403_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.bbrc.2010.03.050","volume":"394","author":"A Salminen","year":"2010","unstructured":"Salminen A, Lehtonen M, Paimela T, Kaarniranta K (2010) Celastrol: molecular targets of Thunder God Vine. Biochem Biophys Res Commun 394:439\u2013442. https:\/\/doi.org\/10.1016\/j.bbrc.2010.03.050","journal-title":"Biochem Biophys Res Commun"},{"key":"12403_CR8","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.cell.2015.05.011","volume":"161","author":"J Liu","year":"2015","unstructured":"Liu J et al (2015) Treatment of obesity with celastrol. Cell 161:999\u20131011. https:\/\/doi.org\/10.1016\/j.cell.2015.05.011","journal-title":"Cell"},{"key":"12403_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.canlet.2021.08.030","volume":"521","author":"HY Lim","year":"2021","unstructured":"Lim HY et al (2021) Celastrol in cancer therapy: recent developments, challenges and prospects. Cancer Lett 521:252\u2013267. https:\/\/doi.org\/10.1016\/j.canlet.2021.08.030","journal-title":"Cancer Lett"},{"key":"12403_CR10","doi-asserted-by":"publisher","first-page":"11144","DOI":"10.1021\/acs.jmedchem.8b01224","volume":"61","author":"E Kyriakou","year":"2018","unstructured":"Kyriakou E et al (2018) Celastrol promotes weight loss in diet-induced obesity by inhibiting the protein tyrosine phosphatases PTP1B and TCPTP in the hypothalamus. J Med Chem 61:11144\u201311157. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01224","journal-title":"J Med Chem"},{"key":"12403_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jep.2012.09.005","volume":"144","author":"J Zhang","year":"2012","unstructured":"Zhang J et al (2012) Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats. J Ethnopharmacol 144:195\u2013200. https:\/\/doi.org\/10.1016\/j.jep.2012.09.005","journal-title":"J Ethnopharmacol"},{"key":"12403_CR12","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.3390\/molecules25153422","volume":"25","author":"S Zhan","year":"2020","unstructured":"Zhan S et al (2020) Oral bioavailability evaluation of celastrol-encapsulated silk fibroin nanoparticles using an optimized LC-MS\/MS method. Molecules 25:3422. https:\/\/doi.org\/10.3390\/molecules25153422","journal-title":"Molecules"},{"key":"12403_CR13","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/ijc.28810","volume":"135","author":"L Zheng","year":"2014","unstructured":"Zheng L et al (2014) Simultaneous NF-kappaB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo. Int J Cancer 135:1721\u20131732. https:\/\/doi.org\/10.1002\/ijc.28810","journal-title":"Int J Cancer"},{"key":"12403_CR14","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJMoa021423","volume":"348","author":"EE Calle","year":"2003","unstructured":"Calle EE et al (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625\u20131638. https:\/\/doi.org\/10.1056\/NEJMoa021423","journal-title":"N Engl J Med"},{"key":"12403_CR15","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","volume":"375","author":"B Lauby-Secretan","year":"2016","unstructured":"Lauby-Secretan B et al (2016) Body fatness and cancer-viewpoint of the IARC Working Group. N Engl J Med 375:794\u2013798. https:\/\/doi.org\/10.1056\/NEJMsr1606602","journal-title":"N Engl J Med"},{"key":"12403_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.coph.2016.07.005","volume":"29","author":"R Kolb","year":"2016","unstructured":"Kolb R, Sutterwala FS, Zhang W (2016) Obesity and cancer: inflammation bridges the two. Curr Opin Pharmacol 29:77\u201389. https:\/\/doi.org\/10.1016\/j.coph.2016.07.005","journal-title":"Curr Opin Pharmacol"},{"key":"12403_CR17","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.cell.2020.11.009","volume":"183","author":"AE Ringel","year":"2020","unstructured":"Ringel AE et al (2020) Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity. Cell 183:1848\u20131866. https:\/\/doi.org\/10.1016\/j.cell.2020.11.009. .e26","journal-title":"Cell"},{"key":"12403_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41574-020-0329-9","volume":"16","author":"BD Hopkins","year":"2020","unstructured":"Hopkins BD, Goncalves MD, Cantley LC (2020) Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer. Nat Rev Endocrinol 16:276\u2013283. https:\/\/doi.org\/10.1038\/s41574-020-0329-9","journal-title":"Nat Rev Endocrinol"},{"key":"12403_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s42255-019-0037-8","volume":"1","author":"AL Ostermann","year":"2019","unstructured":"Ostermann AL et al (2019) Intestinal insulin\/IGF1 signalling through FoxO1 regulates epithelial integrity and susceptibility to colon cancer. Nat Metab 1:371\u2013389. https:\/\/doi.org\/10.1038\/s42255-019-0037-8","journal-title":"Nat Metab"},{"key":"12403_CR20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1177\/1535370218785152","volume":"243","author":"W Zhou","year":"2018","unstructured":"Zhou W, Rowitz BM, Dailey MJ (2018) Insulin\/IGF-1 enhances intestinal epithelial crypt proliferation through PI3K\/Akt, and not ERK signaling in obese humans. Exp Biol Med (Maywood) 243:911\u2013916. https:\/\/doi.org\/10.1177\/1535370218785152","journal-title":"Exp Biol Med (Maywood)"},{"key":"12403_CR21","doi-asserted-by":"publisher","first-page":"102986","DOI":"10.1016\/j.canep.2026.102986","volume":"100","author":"T Lawler","year":"2026","unstructured":"Lawler T et al (2026) Associations between insulin-like growth factor 1, IGF-binding protein 3, and colorectal cancer. Cancer Epidemiol 100:102986. https:\/\/doi.org\/10.1016\/j.canep.2026.102986","journal-title":"Cancer Epidemiol"},{"key":"12403_CR22","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1200\/JCO.2016.67.9712","volume":"34","author":"BD Hopkins","year":"2016","unstructured":"Hopkins BD, Goncalves MD, Cantley LC (2016) Obesity and cancer mechanisms: cancer metabolism. J Clin Oncol 34:4277\u20134283. https:\/\/doi.org\/10.1200\/JCO.2016.67.9712","journal-title":"J Clin Oncol"},{"key":"12403_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4172\/2157-7013.1000211","volume":"6","author":"VK Ramanujan","year":"2015","unstructured":"Ramanujan VK (2015) Metabolic plasticity in cancer cells: reconnecting mitochondrial function to cancer control. J Cell Sci Ther 6:211. https:\/\/doi.org\/10.4172\/2157-7013.1000211","journal-title":"J Cell Sci Ther"},{"key":"12403_CR24","doi-asserted-by":"publisher","first-page":"952371","DOI":"10.3389\/fonc.2022.952371","volume":"12","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, Lin X, Wang G (2022) Targeting SREBP-1-mediated lipogenesis as potential strategies for cancer. Front Oncol 12:952371. https:\/\/doi.org\/10.3389\/fonc.2022.952371","journal-title":"Front Oncol"},{"key":"12403_CR25","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1002\/oby.21654","volume":"24","author":"F McMurray","year":"2016","unstructured":"McMurray F, Patten DA, Harper ME (2016) Reactive oxygen species and oxidative stress in obesity-recent findings and empirical approaches. Obes (Silver Spring) 24:2301\u20132310. https:\/\/doi.org\/10.1002\/oby.21654","journal-title":"Obes (Silver Spring)"},{"key":"12403_CR26","doi-asserted-by":"publisher","first-page":"109212","DOI":"10.1016\/j.celrep.2021.109212","volume":"35","author":"MD Mana","year":"2021","unstructured":"Mana MD et al (2021) High-fat diet-activated fatty acid oxidation mediates intestinal stemness and tumorigenicity. Cell Rep 35:109212. https:\/\/doi.org\/10.1016\/j.celrep.2021.109212","journal-title":"Cell Rep"},{"key":"12403_CR27","doi-asserted-by":"publisher","first-page":"5488","DOI":"10.3390\/ijms24065488","volume":"24","author":"J Pilo","year":"2023","unstructured":"Pilo J et al (2023) 8-Oxoguanine DNA glycosylase 1 upregulation as a risk factor for obesity and colorectal cancer. Int J Mol Sci 24:5488. https:\/\/doi.org\/10.3390\/ijms24065488","journal-title":"Int J Mol Sci"},{"key":"12403_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40170-025-00380-8","volume":"13","author":"EN Devericks","year":"2025","unstructured":"Devericks EN et al (2025) Glutathione peroxidase 4 (GPX4) and obesity interact to impact tumor progression and treatment response in triple-negative breast cancer. Cancer Metab 13:11. https:\/\/doi.org\/10.1186\/s40170-025-00380-8","journal-title":"Cancer Metab"},{"key":"12403_CR29","doi-asserted-by":"publisher","first-page":"116234","DOI":"10.1016\/j.celrep.2025.116234","volume":"44","author":"S Ma","year":"2025","unstructured":"Ma S et al (2025) Disrupting mitochondrial dynamics attenuates ferroptosis and chemotoxicity via upregulating NRF2-mediated FSP1 expression. Cell Rep 44:116234. https:\/\/doi.org\/10.1016\/j.celrep.2025.116234","journal-title":"Cell Rep"},{"key":"12403_CR30","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.trecan.2023.03.003","volume":"9","author":"U Sen","year":"2023","unstructured":"Sen U, Coleman C, Sen T (2023) Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis. Trends Cancer 9:480\u2013489. https:\/\/doi.org\/10.1016\/j.trecan.2023.03.003","journal-title":"Trends Cancer"},{"key":"12403_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/13813455.2021.1988110","volume":"130","author":"Z Tahergorabi","year":"2024","unstructured":"Tahergorabi Z et al (2024) Crosstalk between obesity and cancer: a role for adipokines. Arch Physiol Biochem 130:155\u2013168. https:\/\/doi.org\/10.1080\/13813455.2021.1988110","journal-title":"Arch Physiol Biochem"},{"key":"12403_CR32","doi-asserted-by":"publisher","first-page":"e70113","DOI":"10.1002\/osp4.70113","volume":"12","author":"S Sunita","year":"2026","unstructured":"Sunita S et al (2026) Recent insights into circulating adipokines in obesity: systematic review and meta-analysis. Obes Sci Pract 12:e70113. https:\/\/doi.org\/10.1002\/osp4.70113","journal-title":"Obes Sci Pract"},{"key":"12403_CR33","doi-asserted-by":"publisher","first-page":"21100","DOI":"10.18632\/oncotarget.4228","volume":"6","author":"S Kato","year":"2015","unstructured":"Kato S et al (2015) Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: an explanation for poor outcomes in obese women. Oncotarget 6:21100\u201321119. https:\/\/doi.org\/10.18632\/oncotarget.4228","journal-title":"Oncotarget"},{"key":"12403_CR34","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3390\/ijms22031444","volume":"22","author":"DV Pham","year":"2021","unstructured":"Pham DV, Park PH (2021) Tumor metabolic reprogramming by adipokines as a critical driver of obesity-associated cancer progression. Int J Mol Sci 22:1444. https:\/\/doi.org\/10.3390\/ijms22031444","journal-title":"Int J Mol Sci"},{"key":"12403_CR35","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/j.1365-2362.2008.02028.x","volume":"38","author":"S Kaser","year":"2008","unstructured":"Kaser S et al (2008) Effect of obesity and insulin sensitivity on adiponectin isoform distribution. Eur J Clin Invest 38:827\u2013834. https:\/\/doi.org\/10.1111\/j.1365-2362.2008.02028.x","journal-title":"Eur J Clin Invest"},{"key":"12403_CR36","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1080\/15548627.2017.1332565","volume":"13","author":"SJ Chung","year":"2017","unstructured":"Chung SJ et al (2017) ADIPOQ\/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11\/LKB1-mediated activation of the AMPK-ULK1 axis. Autophagy 13:1386\u20131403. https:\/\/doi.org\/10.1080\/15548627.2017.1332565","journal-title":"Autophagy"},{"key":"12403_CR37","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bcp.2014.12.001","volume":"93","author":"SQ Xing","year":"2015","unstructured":"Xing SQ et al (2015) Adiponectin induces apoptosis in hepatocellular carcinoma through differential modulation of thioredoxin proteins. Biochem Pharmacol 93:221\u2013231. https:\/\/doi.org\/10.1016\/j.bcp.2014.12.001","journal-title":"Biochem Pharmacol"},{"key":"12403_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ygyno.2015.02.012","volume":"137","author":"L Zhang","year":"2015","unstructured":"Zhang L et al (2015) Adiponectin mediates antiproliferative and apoptotic responses in endometrial carcinoma by the AdipoRs\/AMPK pathway. Gynecol Oncol 137:311\u2013320. https:\/\/doi.org\/10.1016\/j.ygyno.2015.02.012","journal-title":"Gynecol Oncol"},{"key":"12403_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11010-019-03586-9","volume":"461","author":"AA Ramzan","year":"2019","unstructured":"Ramzan AA et al (2019) Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol Cell Biochem 461:37\u201346. https:\/\/doi.org\/10.1007\/s11010-019-03586-9","journal-title":"Mol Cell Biochem"},{"key":"12403_CR40","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1007\/s11010-023-04670-x","volume":"478","author":"I Akrida","year":"2023","unstructured":"Akrida I, Papadaki H (2023) Adipokines and epithelial-mesenchymal transition (EMT) in cancer. Mol Cell Biochem 478:2419\u20132433. https:\/\/doi.org\/10.1007\/s11010-023-04670-x","journal-title":"Mol Cell Biochem"},{"key":"12403_CR41","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/onc.2017.357","volume":"37","author":"CH Wang","year":"2018","unstructured":"Wang CH et al (2018) Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties. Oncogene 37:589\u2013600. https:\/\/doi.org\/10.1038\/onc.2017.357","journal-title":"Oncogene"},{"key":"12403_CR42","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1139\/cjpp-2020-0377","volume":"99","author":"C Miethe","year":"2021","unstructured":"Miethe C, Torres L, Beristain J, Zamora M, Price RS (2021) The role of visfatin and resistin in an in vitro model of obesity-induced invasive liver cancer. Can J Physiol Pharmacol 99:839\u2013846. https:\/\/doi.org\/10.1139\/cjpp-2020-0377","journal-title":"Can J Physiol Pharmacol"},{"key":"12403_CR43","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1194\/jlr.M800019-JLR200","volume":"49","author":"I Murano","year":"2008","unstructured":"Murano I et al (2008) Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 49:1562\u20131568. https:\/\/doi.org\/10.1194\/jlr.M800019-JLR200","journal-title":"J Lipid Res"},{"key":"12403_CR44","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cell.2009.12.052","volume":"140","author":"EJ Park","year":"2010","unstructured":"Park EJ et al (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197\u2013208. https:\/\/doi.org\/10.1016\/j.cell.2009.12.052","journal-title":"Cell"},{"key":"12403_CR45","doi-asserted-by":"publisher","first-page":"9453","DOI":"10.1073\/pnas.1821068116","volume":"116","author":"Z Ji","year":"2019","unstructured":"Ji Z, He L, Regev A, Struhl K (2019) Inflammatory regulatory network mediated by the joint action of NF-kappaB, STAT3, and AP-1 factors is involved in many human cancers. Proc Natl Acad Sci U S A 116:9453\u20139462. https:\/\/doi.org\/10.1073\/pnas.1821068116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12403_CR46","doi-asserted-by":"publisher","first-page":"8859","DOI":"10.1038\/s41598-018-27184-9","volume":"8","author":"J Gyamfi","year":"2018","unstructured":"Gyamfi J, Lee YH, Eom M, Choi J (2018) Interleukin-6\/STAT3 signalling regulates adipocyte-induced epithelial-mesenchymal transition in breast cancer cells. Sci Rep 8:8859. https:\/\/doi.org\/10.1038\/s41598-018-27184-9","journal-title":"Sci Rep"},{"key":"12403_CR47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.2279","volume":"17","author":"B Vandanmagsar","year":"2011","unstructured":"Vandanmagsar B et al (2011) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 17:179\u2013188. https:\/\/doi.org\/10.1038\/nm.2279","journal-title":"Nat Med"},{"key":"12403_CR48","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli F et al (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15:1170\u20131178. https:\/\/doi.org\/10.1038\/nm.2028","journal-title":"Nat Med"},{"key":"12403_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.canlet.2021.01.003","volume":"502","author":"RM Goncalves","year":"2021","unstructured":"Goncalves RM et al (2021) COX-2 promotes mammary adipose tissue inflammation, local estrogen biosynthesis, and carcinogenesis in high-sugar\/fat diet-treated mice. Cancer Lett 502:44\u201357. https:\/\/doi.org\/10.1016\/j.canlet.2021.01.003","journal-title":"Cancer Lett"},{"key":"12403_CR50","doi-asserted-by":"publisher","first-page":"112332","DOI":"10.1016\/j.intimp.2024.112332","volume":"136","author":"H Xie","year":"2024","unstructured":"Xie H et al (2024) Obesity-associated metabolic inflammation promotes triple-negative breast cancer progression through the interleukin-6\/STAT3\/pentraxin 3\/matrix metalloproteinase 7 axis. Int Immunopharmacol 136:112332. https:\/\/doi.org\/10.1016\/j.intimp.2024.112332","journal-title":"Int Immunopharmacol"},{"key":"12403_CR51","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1476-4598-9-79","volume":"9","author":"B Peng","year":"2010","unstructured":"Peng B et al (2010) HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0\/G1 in a thiol-containing-agent-reversible manner. Mol Cancer 9:79. https:\/\/doi.org\/10.1186\/1476-4598-9-79","journal-title":"Mol Cancer"},{"key":"12403_CR52","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/17425255.2023.2294042","volume":"19","author":"X Jiang","year":"2023","unstructured":"Jiang X et al (2023) Toxic metabolites and metabolic soft spots of celastrol based on glutathione metabolic capture and high-resolution mass spectrometry. Expert Opin Drug Metab Toxicol 19:1023\u20131032. https:\/\/doi.org\/10.1080\/17425255.2023.2294042","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"12403_CR53","doi-asserted-by":"publisher","first-page":"10907","DOI":"10.2147\/IJN.S539586","volume":"20","author":"P He","year":"2025","unstructured":"He P et al (2025) From physicochemical constraints to clinical prospects of celastrol: challenges and nanodelivery strategies. Int J Nanomed 20:10907\u201310931. https:\/\/doi.org\/10.2147\/IJN.S539586","journal-title":"Int J Nanomed"},{"key":"12403_CR54","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2147\/IJN.S232603","volume":"15","author":"J Li","year":"2020","unstructured":"Li J et al (2020) Celastrol self-stabilized nanoparticles for effective treatment of melanoma. Int J Nanomed 15:1205\u20131214. https:\/\/doi.org\/10.2147\/IJN.S232603","journal-title":"Int J Nanomed"},{"key":"12403_CR55","doi-asserted-by":"publisher","first-page":"673209","DOI":"10.3389\/fphar.2021.673209","volume":"12","author":"PR Wagh","year":"2021","unstructured":"Wagh PR, Desai P, Prabhu S, Wang J (2021) Nanotechnology-based celastrol formulations and their therapeutic applications. Front Pharmacol 12:673209. https:\/\/doi.org\/10.3389\/fphar.2021.673209","journal-title":"Front Pharmacol"},{"key":"12403_CR56","doi-asserted-by":"publisher","first-page":"114882","DOI":"10.1016\/j.biopha.2023.114882","volume":"163","author":"C Wang","year":"2023","unstructured":"Wang C et al (2023) Celastrol as an emerging anticancer agent: current status, challenges and therapeutic strategies. Biomed Pharmacother 163:114882. https:\/\/doi.org\/10.1016\/j.biopha.2023.114882","journal-title":"Biomed Pharmacother"},{"key":"12403_CR57","doi-asserted-by":"publisher","first-page":"558741","DOI":"10.3389\/fphar.2020.558741","volume":"11","author":"J Shi","year":"2020","unstructured":"Shi J et al (2020) Celastrol: a review of useful strategies overcoming its limitation in anticancer application. Front Pharmacol 11:558741. https:\/\/doi.org\/10.3389\/fphar.2020.558741","journal-title":"Front Pharmacol"},{"key":"12403_CR58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jcjd.2018.07.002","volume":"43","author":"X Zhang","year":"2019","unstructured":"Zhang X et al (2019) Celastrol reverses palmitic acid-induced insulin resistance in HepG2 cells via restoring the miR-223 and GLUT4 pathway. Can J Diabetes 43:165\u2013172. https:\/\/doi.org\/10.1016\/j.jcjd.2018.07.002","journal-title":"Can J Diabetes"},{"key":"12403_CR59","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13072-019-0290-9","volume":"12","author":"P Senapati","year":"2019","unstructured":"Senapati P et al (2019) Hyperinsulinemia promotes aberrant histone acetylation in triple-negative breast cancer. Epigenetics Chromatin 12:44. https:\/\/doi.org\/10.1186\/s13072-019-0290-9","journal-title":"Epigenetics Chromatin"},{"key":"12403_CR60","doi-asserted-by":"publisher","first-page":"6814","DOI":"10.1002\/jcp.26547","volume":"233","author":"X Zhang","year":"2018","unstructured":"Zhang X et al (2018) Celastrol reverses palmitic acid (PA)-caused TLR4-MD2 activation-dependent insulin resistance via disrupting MD2-related cellular binding to PA. J Cell Physiol 233:6814\u20136824. https:\/\/doi.org\/10.1002\/jcp.26547","journal-title":"J Cell Physiol"},{"key":"12403_CR61","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/CAD.0000000000000621","volume":"29","author":"T Bufu","year":"2018","unstructured":"Bufu T et al (2018) Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K\/AKT signaling pathway. Anticancer Drugs 29:530\u2013538. https:\/\/doi.org\/10.1097\/CAD.0000000000000621","journal-title":"Anticancer Drugs"},{"key":"12403_CR62","first-page":"808","volume":"12","author":"H Ni","year":"2019","unstructured":"Ni H, Han Y, Jin X (2019) Celastrol inhibits colon cancer cell proliferation by downregulating miR-21 and the PI3K\/AKT\/GSK-3beta pathway. Int J Clin Exp Pathol 12:808\u2013816","journal-title":"Int J Clin Exp Pathol"},{"key":"12403_CR63","doi-asserted-by":"publisher","first-page":"658092","DOI":"10.3389\/fphar.2021.658092","volume":"12","author":"CJ Zhang","year":"2021","unstructured":"Zhang CJ et al (2021) Celastrol attenuates lipid accumulation and stemness of clear cell renal cell carcinoma via the CAV-1\/LOX-1 pathway. Front Pharmacol 12:658092. https:\/\/doi.org\/10.3389\/fphar.2021.658092","journal-title":"Front Pharmacol"},{"key":"12403_CR64","doi-asserted-by":"publisher","first-page":"8977","DOI":"10.2147\/OTT.S187315","volume":"11","author":"X Li","year":"2018","unstructured":"Li X et al (2018) Celastrol induces ubiquitin-dependent degradation of mTOR in breast cancer cells. Onco Targets Ther 11:8977\u20138985. https:\/\/doi.org\/10.2147\/OTT.S187315","journal-title":"Onco Targets Ther"},{"key":"12403_CR65","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.7150\/ijbs.73890","volume":"18","author":"N Fan","year":"2022","unstructured":"Fan N et al (2022) Covalent inhibition of pyruvate kinase M2 reprograms metabolic and inflammatory pathways in hepatic macrophages against non-alcoholic fatty liver disease. Int J Biol Sci 18:5260\u20135275. https:\/\/doi.org\/10.7150\/ijbs.73890","journal-title":"Int J Biol Sci"},{"key":"12403_CR66","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s10020-025-01259-6","volume":"31","author":"C Yu","year":"2025","unstructured":"Yu C et al (2025) Celastrol improves endothelial function in diet-induced obesity mice via attenuating endoplasmic reticulum stress through activation of the AMPK pathway. Mol Med 31:233. https:\/\/doi.org\/10.1186\/s10020-025-01259-6","journal-title":"Mol Med"},{"key":"12403_CR67","doi-asserted-by":"publisher","first-page":"e62068","DOI":"10.1371\/journal.pone.0062068","volume":"8","author":"JE Kim","year":"2013","unstructured":"Kim JE et al (2013) Celastrol, an NF-kappaB inhibitor, improves insulin resistance and attenuates renal injury in db\/db mice. PLoS ONE 8:e62068. https:\/\/doi.org\/10.1371\/journal.pone.0062068","journal-title":"PLoS ONE"},{"key":"12403_CR68","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.2337\/db18-0146","volume":"67","author":"K Pfuhlmann","year":"2018","unstructured":"Pfuhlmann K et al (2018) Celastrol-induced weight loss is driven by hypophagia and independent from UCP1. Diabetes 67:2456\u20132465. https:\/\/doi.org\/10.2337\/db18-0146","journal-title":"Diabetes"},{"key":"12403_CR69","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1016\/j.csbj.2022.06.042","volume":"20","author":"P Chen","year":"2022","unstructured":"Chen P et al (2022) Celastrol inhibits the proliferation and migration of MCF-7 cells through the leptin-triggered PI3K\/AKT pathway. Comput Struct Biotechnol J 20:3173\u20133181. https:\/\/doi.org\/10.1016\/j.csbj.2022.06.042","journal-title":"Comput Struct Biotechnol J"},{"key":"12403_CR70","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/nature08991","volume":"464","author":"M Iwabu","year":"2010","unstructured":"Iwabu M et al (2010) Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca2\u2009+\u2009and AMPK\/SIRT1. Nature 464:1313\u20131319. https:\/\/doi.org\/10.1038\/nature08991","journal-title":"Nature"},{"key":"12403_CR71","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.advms.2026.05.001","volume":"71","author":"M D\u00ebrmaku-Sopjani","year":"2026","unstructured":"D\u00ebrmaku-Sopjani M et al (2026) AMPK signaling in cancer: dual roles, molecular mechanisms, and therapeutic potential. Adv Med Sci 71:196\u2013211. https:\/\/doi.org\/10.1016\/j.advms.2026.05.001","journal-title":"Adv Med Sci"},{"key":"12403_CR72","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1079\/PNS2001110","volume":"60","author":"SW Coppack","year":"2001","unstructured":"Coppack SW (2001) Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60:349\u2013356. https:\/\/doi.org\/10.1079\/PNS2001110","journal-title":"Proc Nutr Soc"},{"key":"12403_CR73","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.18632\/aging.101302","volume":"9","author":"D Luo","year":"2017","unstructured":"Luo D, Guo Y, Cheng Y, Zhao J, Wang Y, Rong J (2017) Natural product celastrol suppressed macrophage M1 polarization against inflammation in diet-induced obese mice via regulating Nrf2\/HO-1, MAP kinase and NF-kappaB pathways. Aging 9:2069\u20132082. https:\/\/doi.org\/10.18632\/aging.101302","journal-title":"Aging"},{"key":"12403_CR74","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ptr.6800","volume":"35","author":"X Yang","year":"2021","unstructured":"Yang X et al (2021) Celastrol alleviates metabolic disturbance in high-fat diet-induced obese mice through increasing energy expenditure by ameliorating metabolic inflammation. Phytother Res 35:297\u2013310. https:\/\/doi.org\/10.1002\/ptr.6800","journal-title":"Phytother Res"},{"key":"12403_CR75","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/s41401-020-00572-6","volume":"42","author":"CJ Zhang","year":"2021","unstructured":"Zhang CJ et al (2021) Celastrol induces lipophagy via the LXRalpha\/ABCA1 pathway in clear cell renal cell carcinoma. Acta Pharmacol Sin 42:1472\u20131485. https:\/\/doi.org\/10.1038\/s41401-020-00572-6","journal-title":"Acta Pharmacol Sin"},{"key":"12403_CR76","doi-asserted-by":"publisher","first-page":"157275","DOI":"10.1016\/j.phymed.2025.157275","volume":"148","author":"Y Li","year":"2025","unstructured":"Li Y et al (2025) Celastrol liposomes enhance anti-PD-L1 in triple-negative breast cancer by reprogramming the immunosuppressive microenvironment driven by cancer-associated adipocytes. Phytomedicine 148:157275. https:\/\/doi.org\/10.1016\/j.phymed.2025.157275","journal-title":"Phytomedicine"},{"key":"12403_CR77","doi-asserted-by":"publisher","first-page":"116025","DOI":"10.1016\/j.intimp.2025.116025","volume":"169","author":"Y Yang","year":"2026","unstructured":"Yang Y et al (2026) Celastrol inhibits intrahepatic cholangiocarcinogenesis through dual suppression of glycolysis and tumor-associated macrophages. Int Immunopharmacol 169:116025. https:\/\/doi.org\/10.1016\/j.intimp.2025.116025","journal-title":"Int Immunopharmacol"},{"key":"12403_CR78","doi-asserted-by":"publisher","first-page":"8851","DOI":"10.1038\/s41598-020-65773-9","volume":"10","author":"T Huang","year":"2020","unstructured":"Huang T et al (2020) Preparation of high drug-loading celastrol nanosuspensions and their anti-breast cancer activities in vitro and in vivo. Sci Rep 10:8851. https:\/\/doi.org\/10.1038\/s41598-020-65773-9","journal-title":"Sci Rep"},{"key":"12403_CR79","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.2022.6147","volume":"327","author":"PJ Goodwin","year":"2022","unstructured":"Goodwin PJ et al (2022) Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial. JAMA 327:1963\u20131973. https:\/\/doi.org\/10.1001\/jama.2022.6147","journal-title":"JAMA"},{"key":"12403_CR80","doi-asserted-by":"publisher","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","volume":"7","author":"L Wang","year":"2024","unstructured":"Wang L, Xu R, Kaelber DC, Berger NA (2024) Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open 7:e2421305. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.21305","journal-title":"JAMA Netw Open"},{"key":"12403_CR81","doi-asserted-by":"publisher","first-page":"7392","DOI":"10.1158\/0008-5472.CAN-10-2027","volume":"70","author":"KR Patel","year":"2010","unstructured":"Patel KR et al (2010) Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70:7392\u20137399. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2027","journal-title":"Cancer Res"},{"key":"12403_CR82","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/jn\/nxz029","volume":"149","author":"LM Howells","year":"2019","unstructured":"Howells LM et al (2019) Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial. J Nutr 149:1133\u20131139. https:\/\/doi.org\/10.1093\/jn\/nxz029","journal-title":"J Nutr"},{"key":"12403_CR83","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1053\/j.gastro.2018.05.031","volume":"155","author":"M Cruz-Correa","year":"2018","unstructured":"Cruz-Correa M et al (2018) Efficacy and safety of curcumin in treatment of intestinal adenomas in patients with familial adenomatous polyposis. Gastroenterology 155:668\u2013673. https:\/\/doi.org\/10.1053\/j.gastro.2018.05.031","journal-title":"Gastroenterology"},{"key":"12403_CR84","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2468-1253(19)30409-1","volume":"5","author":"YX Chen","year":"2020","unstructured":"Chen YX et al (2020) Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol 5:267\u2013275. https:\/\/doi.org\/10.1016\/S2468-1253(19)30409-1","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12403-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12403-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12403-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:41:56Z","timestamp":1784266916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12403-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12403"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12403-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"13 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI models such as Grammarly were used for the refinement of the English Language in this manuscript.","order":3,"name":"Ethics","label":"AI utilization","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1189"}}